Relapse-free survial and target identification to enhance response with neoadjuvant and adjuvant dabrafenib + trametinib treatment compared to standard-of-care surgery in patients with high-risk resectable BRAF-mutant metastatic melanoma

Home / Abstract / Relapse-free survial and target identification to enhance response with neoadjuvant and adjuvant dabrafenib + trametinib treatment compared to standard-of-care surgery in patients with high-risk resectable BRAF-mutant metastatic melanoma